Aliskiren trial terminated for lack of beneficial effects

In a stunning development, Novartis said Tuesday that it will terminate the late-stage ALTITUDE study investigating Rasilez (aliskiren) in patients with type 2 diabetes and renal impairment on the recommendation of an independent data monitoring committee.

Read more on our partner site UKidney

Read 792 times

Last modified on Tuesday, 20 December 2011 23:40

Scroll to Top